Results 221 to 230 of about 87,754 (241)

The interaction of lipolysis products of very low density lipoprotein with plasma high density lipoprotein (HDL): perfusate HDL with plasma HDL subfractions

Biochemistry and Cell Biology, 1987
The nature of the interaction of high density lipoproteins (HDL), formed during lipolysis of human very low density lipoprotein (VLDL) by perfused rat heart, with subfractions of human plasma HDL was investigated. Perfusate HDL, containing apoliproproteins (apo) E, C-II, and C-III but no apo A-I or A-II, was incubated with a subfraction of HDL (HDL-A)
S. P. Tam, W. C. Breckenridge
openaire   +3 more sources

Paraoxonase Genotypes, Lipoprotein Lipase Activity, and HDL

Arteriosclerosis, Thrombosis, and Vascular Biology, 1996
Paraoxonase, an enzyme associated with the high density lipoprotein (HDL) particle, hydrolyzes paraoxon, the active metabolite of the insecticide parathion. Several studies have shown that paraoxonase levels in humans have a distribution characteristic of two alleles, one with low activity and the other with high activity.
Rebecca J. Richter, Clement E. Furlong, Richard Humbert, John D. Brunzell, Alberto Zambon, John E. Hokanson, D.N. Nevin   +6 more
openaire   +3 more sources

Studies on Human Serum High-Density Lipoproteins (HDL) IV. Isolation of Lipoprotein Families after Incubation of HDL

Scandinavian Journal of Clinical & Laboratory Investigation, 1975
The high-density lipoproteins (HDL) of human serum appear to be unstable and easily exposed to chemical changes during isolation. In earlier studies we have isolated and purified HDL subfractions either in the presence of an SH-blocking agent, DTNB, or in the cold.
Ulf Svanberg, A. Gustafson, Sven-Olof Olofsson   +2 more
openaire   +3 more sources

High-density Lipoprotein (HDL) Dysfunction and the Future of HDL

Current Vascular Pharmacology, 2018
Although High Density Lipoprotein Cholesterol (HDL-C) levels are inversely proportional to cardiovascular risk in many studies, recent pharmacological interventional studies with HDL-C raising strategies did not show a benefit in terms of vascular events. The HDL particle is heterogenous with anti-atherogenic functions and non-vascular effects.
openaire   +3 more sources

HDL-binding lipoproteins on human fetal hepatocytes

Bulletin of Experimental Biology and Medicine, 1998
Two types of binding sites for high-density lipoproteins (Kd=1 μg/ml and 20 μg/ml) were identified on human fetal hepatocytes and designated as P1 and P2. Ligand blotting has shown that P1 site is protein with Mr 100 kD and P2 site involves two proteins with Mr 105 and 110 kD.
L. N. Kask, M. A. Kornyushin, Gennady T. Sukhikh, Baranova In, Yu. A. Blidchenko, Vadim S. Repin, T. G. Vishnyakova, M. V. Eremeeva, A. V. Bocharov   +8 more
openaire   +2 more sources

High Density Lipoprotein (HDL) Modulation Targets.

Drugs of the future, 2010
Given the strong genetic determinants of favorable HDL-C levels, the ability to procure the cardiovascular disease and longevity benefits associated with this mediator of the reverse cholesterol transport pathway through pharmaceutical intervention is challenging.
Robert C. Block, Shaker A. Mousa, Shaymaa S Mousa   +2 more
openaire   +3 more sources

High Density Lipoproteins (HDL) and the Oxidative Hypothesis of Atherosclerosis

cclm, 1999
Abstract The oxidative hypothesis of atherosclerosis classically implies a central role for low density lipoprotein (LDL) oxidation. However, new antiatherogenic properties have been recognized for high density lipoproteins (HDL), apart from their ability to reverse cholesterol transport.
Jean-Louis Beaudeux, Dominique Bonnefont-Rousselot, J. Peynet, Patrice Thérond, J. Delattre, Alain Legrand   +5 more
openaire   +3 more sources

High-density lipoproteins (HDL) composition and function in preeclampsia

Archives of Gynecology and Obstetrics, 2018
To evaluate (a) the properties of high-density lipoproteins (HDL)/cholesterol, which include apolipoprotein A-1 (ApoA1) and paraoxonase1 (PON1), both are negative predictors of cardiovascular risk and (b) HDL function, among women with preeclampsia (PE).
Tali Zitman-Gal, Tali Zitman-Gal, Tal Biron-Shental, Tal Biron-Shental, Jacob Vaya, Moran Agassi-Zaitler, Soliman Khatib, Keren Tzadikevitch-Geffen, Keren Tzadikevitch-Geffen, Meital Ohana, Sydney Benchetrit, Sydney Benchetrit, Yael Einbinder   +12 more
openaire   +3 more sources

Low‐Density Lipoproteins, High‐Density Lipoproteins (HDL), and HDL‐Associated Proteins Differentially Modulate Chronic Myelogenous Leukemia Cell Viability

Lipids, 2020
AbstractCellular lipid metabolism, lipoprotein interactions, and liver X receptor (LXR) activation have been implicated in the pathophysiology and treatment of cancer, although findings vary across cancer models and by lipoprotein profiles. In this study, we investigated the effects of human‐derived low‐density lipoproteins (LDL), high‐density ...
Catherine J. Andersen, Lydia Dupree, Kristina Murray, Nicholas Ragonesi, Kaley McMullen, Layra Cintrón‐Rivera, Adam Doerr   +6 more
openaire   +2 more sources

Plasma lipoprotein abnormalities in a case of primary high‐density‐lipoprotein (HDL) deficiency

Clinical Genetics, 1975
A 53‐year‐old patient with primary HDL‐deficiency is reported. About 2% of the normal concentration of alpha1 HDL was present in his plasma. The alphal‐high‐density‐lipopro‐teins separated into two fast‐moving components in polyacrylamide gel electrophoresis.
H. J. Menzel, W. Schoenborn, G. Utermann
openaire   +3 more sources